• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    bluebird bio Reports Third Quarter 2024 Results and Highlights Operational Progress and 2024 Guidance

    11/14/24 7:00:00 AM ET
    $BLUE
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $BLUE alert in real time by email

    - 74 patient starts completed or scheduled to date in 2024 across bluebird's commercial portfolio -

    - Third quarter 2024 net revenue of $10.6 million reflects quarter-to-quarter fluctuations in drug product infusions; anticipate at least $25 million of net revenue in the fourth quarter -

    - Management to host conference call today, November 14, 2024 at 8:00 am ET -

    bluebird bio, Inc. (NASDAQ:BLUE) ("bluebird bio" or the "Company") today reported third quarter results and business highlights for the quarter ended September 30, 2024, including recent commercial and operational progress.

    "Patient starts more than doubled from our second to third quarter update, providing clear evidence that our commercial launches continued to accelerate," said Andrew Obenshain, chief executive officer. "This momentum, coupled with steps we took in the third quarter to increase manufacturing capacity for ZYNTEGLO and optimize our cost structure, is propelling bluebird forward on our path to becoming a sustainable commercial gene therapy company. We remain focused on securing additional cash resources to extend our runway, which we believe would enable us to achieve this vision and reach cash flow break-even in the second half of 2025."

    COMMERCIAL LAUNCH UPDATES

    Continued commercial momentum across the portfolio

    • 57 patient starts completed to date in 2024 (35 ZYNTEGLO, 17 LYFGENIA, 5 SKYSONA).
    • 17 additional starts scheduled through the remainder of 2024.
    • Evidence of strong commercial demand, with 30 patient starts already scheduled in 2025, supporting the potential for cash flow breakeven in the second half of 2025.
    • More than 70 activated QTCs, with 40% having initiated or completed treatment for at least one patient.

    Validated access and reimbursement strategy is driving favorable coverage landscape

    • To date, more than half of all states have affirmed coverage for LYFGENIA through a preferred drug list or published coverage criteria.
    • Nearly 50% of Medicaid-insured individuals with sickle cell disease in the U.S. live in a state that has already completed prior authorization approval for the use of LYFGENIA for at least one patient.
    • Multiple outcomes-based agreements are published and in place for LYFGENIA with national commercial payer organizations, representing more than 200 million U.S. lives.

    DATA PRESENTATIONS AT ASH 2024

    Updated data from the Company's lentiviral vector (LVV) gene addition programs in patients with sickle cell disease who have a history of vaso-occlusive events and patients with beta-thalassemia who require regular blood transfusions will be presented at the 66th American Society of Hematology (ASH) Annual Meeting and Exposition. The meeting will take place December 7-10, 2024 at the San Diego Convention Center and online.

    SICKLE CELL DISEASE DATA

    • Oral Presentation [#511]: An Update on Lovotibeglogene Autotemcel (lovo-cel) Clinical Trials for Sickle Cell Disease (SCD) and Analysis of Early Predictors of Response to Lovo-cel
    • Presenting Author: Dr. Stacey Rifkin-Zenenberg (Hackensack)
    • Date/Time: Sunday, December 8, 2024, 9:30 a.m. – 11:00 a.m. PT
    • Poster Presentation [#3576]: Participants with a History of Stroke in Lovotibeglogene Autotemcel (lovo-cel) Clinical Trials
    • Presenting Author: Dr. Jen Jaroscak (The Medical University of South Carolina)
    • Date/Time: Sunday, December 8, 2024, 6:00 p.m. – 8:00 p.m. PT

    BETA-THALASSEMIA DATA

    • Poster Presentation [#2194]: Betibeglogene Autotemcel (beti-cel) Gene Addition Therapy results in durable Hemoglobin A (HbA) Production with up to 10 Years of Follow-Up in Participants with Transfusion-Dependent β-Thalassemia
    • Presenting Author: Dr. Alexis A Thompson (Children's Hospital of Philadelphia)
    • Date/Time: Saturday, December 7, 2024, 5:30 p.m. – 7:30 p.m. PT

    Abstracts outlining bluebird bio's accepted data at ASH 2024 are available on the ASH conference website.

    THIRD QUARTER FINANCIAL HIGHLIGHTS

    • Cash Position: The Company's cash, cash equivalents and restricted cash balance was approximately $118.7 million, including restricted cash of approximately $48.0 million, as of September 30, 2024.



      bluebird and Hercules are engaging collaboratively as bluebird works to secure adequate cash runway to obtain additional financing and reach cash flow break-even. Based on current forecasts, which assume continued cost-saving initiatives, successfully renegotiating key contracts, and continued collaborative engagement from Hercules, we expect our existing cash and cash equivalents will enable us to fund our operations into the first quarter of 2025.



      The Company anticipates quarterly cash flow break-even in the second half of 2025, assuming it scales to approximately 40 drug product deliveries per quarter and obtains additional cash resources to extend its runway.
    • Revenue, net: Total revenue, net was $10.6 million for the three months ended September 30, 2024, compared to $12.3 million for the three months ended September 30, 2023, driven by quarter-to-quarter variability in drug product infusions.



      Revenue for the third quarter includes revenue from LYFGENIA, following the completion of the first infusion for sickle cell disease.



      bluebird previously guided to an anticipated reduction of net revenue in the third quarter; the Company now anticipates net revenue of at least $25 million in the fourth quarter 2024, as previously reported patient starts are infused.
    • Cost of Product Revenue: Cost of product revenue was $11.8 million for the three months ended September 30, 2024, compared to $9.1 million for the three months ended September 30, 2023.
    • SG&A Expenses: Selling, general and administrative expenses were $39.8 million for the three months ended September 30, 2024, compared to $40.8 million for the three months ended September 30, 2023. The decrease of $1.0 million was primarily driven by decrease in employee compensation, benefit, and other headcount related expenses, commercial expenses, and facility fees, partially offset by increased professional services fees.
    • R&D Expenses: Research and development expenses were $23.2 million for the three months ended September 30, 2024, compared to $58.5 million for the three months ended September 30, 2023. The decrease of $35.3 million was primarily driven by material production shift to inventory and cost of product revenue as well as decreased employee compensation, benefit, and other headcount related expenses, consulting fees, and facility and information technology fees.
    • Net income (loss): Net loss was $60.8 million for the three months ended September 30, 2024, compared to a net loss of $87.2 million for the three months ended September 30, 2023.

    CONFERENCE CALL DETAILS

    bluebird will hold a conference call to discuss its third quarter 2024 results and business updates today, Wednesday, November 14, 2024, at 8:00 am ET.

    To access the live conference call via telephone, please register at this link to receive a dial in number and unique PIN.

    To access the live webcast, please visit the "Events & Presentations" page within the Investors & Media section of the bluebird bio website at http://investor.bluebirdbio.com. A replay of the webcast will be available on the bluebird bio website for 90 days following the event.

    About bluebird bio, Inc.

    bluebird bio is pursuing curative gene therapies to give patients and their families more bluebird days.

    Founded in 2010, bluebird has been setting the standard for gene therapy for more than a decade—first as a scientific pioneer and now as a commercial leader. bluebird has an unrivaled track record in bringing the promise of gene therapy out of clinical studies and into the real-world setting, having secured FDA approvals for three therapies in under two years. Today, we are proving and scaling the commercial model for gene therapy and delivering innovative solutions for access to patients, providers, and payers.

    With a dedicated focus on severe genetic diseases, bluebird has the largest and deepest ex-vivo gene therapy data set in the field, with industry-leading programs for sickle cell disease, β-thalassemia and cerebral adrenoleukodystrophy. We custom design each of our therapies to address the underlying cause of disease and have developed in-depth and effective analytical methods to understand the safety of our lentiviral vector technologies and drive the field of gene therapy forward.

    bluebird continues to forge new paths as a standalone commercial gene therapy company, combining our real-world experience with a deep commitment to patient communities and a people-centric culture that attracts and grows a diverse flock of dedicated birds.

    bluebird bio, LYFGENIA, ZYNTEGLO and SKYSONA are registered trademarks of bluebird bio, Inc. All rights reserved.

    Forward-Looking Statements

    This press release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. All statements that are not statements of historical facts are, or may be deemed to be, forward-looking statements, such as statements regarding future results of operations and financial position, including anticipated revenue for the fourth quarter; the number of anticipated patient starts across bluebird's portfolio of therapies; the Company's anticipated cash runway and path to cash flow breakeven in the second half of 2025, including the impact of continued cost-saving initiatives, bluebird's ability to successfully renegotiate key contracts, and continued collaborative engagement from Hercules, and the Company's ability to obtain additional cash resources; the Company's expectations with respect to the commercialization of its products, including without limitation, patient demand, the timing and amount of revenue recognition; and the Company's ability to establish favorable coverage for its therapies. Such forward-looking statements are based on historical performance and current expectations and projections about bluebird's future goals, plans and objectives and involve inherent risks, assumptions and uncertainties, including internal or external factors that could delay, divert or change any of them in the next several years, that are difficult to predict, may be beyond bluebird's control and could cause bluebird's future goals, plans and objectives to differ materially from those expressed in, or implied by, the statements. No forward-looking statement can be guaranteed. Forward-looking statements in this press release should be evaluated together with the many risks and uncertainties that affect bluebird bio's business, particularly those identified in the risk factors discussion in bluebird bio's Annual Report on Form 10-K for the year ended December 31, 2023, as updated by its subsequent Quarterly Reports on Form 10-Q, Current Reports on Form 8-K and other filings with the Securities and Exchange Commission. These risks and uncertainties include, but are not limited to: delays and challenges in bluebird's commercialization and manufacturing of its products, including challenges in manufacturing vector for ZYNTEGLO and SKYSONA to meet current demand; the internal and external costs required for bluebird's ongoing and planned activities, and the resulting impact on expense and use of cash, has been, and may in the future be, higher than expected, which has caused bluebird, and may in the future cause bluebird, to use cash more quickly than it expects or change or curtail some of its plans or both; substantial doubt exists regarding bluebird's ability to continue as a going concern; bluebird's expectations as to expenses, cash usage and cash needs may prove not to be correct for other reasons such as changes in plans or actual events being different than bluebird's assumptions; the risk that additional funding may not be available on acceptable terms, or at all; risks related to bluebird's loan agreement, including the risk that operating restrictions could adversely affect bluebird's ability to conduct its business, the risk that bluebird will not achieve milestones required to access future tranches under the agreement, and the risk that bluebird will fail to comply with covenants under the agreement, including with respect to required cash and revenue levels, which could result in an event of default; the risk that the efficacy and safety results from bluebird's prior and ongoing clinical trials will not continue or be seen in the commercial context; the risk that the QTCs experience delays in their ability to enroll or treat patients; the risk that bluebird experiences delays in establishing operational readiness across its supply chain ; the risk that there is not sufficient patient demand or payer reimbursement to support continued commercialization of the Company's therapies; the risk of insertional oncogenic or other safety events associated with lentiviral vector, drug product, or myeloablation, including the risk of hematologic malignancy; the risk that bluebird's products, including LYFGENIA, will not be successfully commercialized; and risks related to compliance with Nasdaq continued listing requirements. The forward-looking statements included in this document are made only as of the date of this document and except as otherwise required by applicable law, bluebird bio undertakes no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events, changed circumstances or otherwise.

    bluebird bio, Inc.

    Condensed Consolidated Statements of Operations

    (in thousands, except per share data)

    (unaudited)

     

    For the three months ended September 30,

     

    For the nine months ended

    September 30,

     

     

    2024

     

     

     

    2023

     

     

     

    2024

     

     

     

    2023

     

     

     

     

    (As Restated)

     

     

     

    (As Restated)

    Revenue:

     

     

     

     

     

     

     

    Product revenue, net

    $

    10,612

     

     

    $

    12,281

     

     

    $

    45,274

     

     

    $

    21,414

     

    Other revenue

     

    —

     

     

     

    111

     

     

     

    12

     

     

     

    249

     

    Total revenues

     

    10,612

     

     

     

    12,392

     

     

     

    45,286

     

     

     

    21,663

     

    Cost of product revenue

     

    11,781

     

     

     

    9,126

     

     

     

    66,591

     

     

     

    21,335

     

    Gross margin

     

    (1,169

    )

     

     

    3,266

     

     

     

    (21,305

    )

     

     

    328

     

    Operating expenses:

     

     

     

     

     

     

     

    Selling, general and administrative

     

    39,765

     

     

     

    40,771

     

     

     

    136,479

     

     

     

    118,700

     

    Research and development

     

    23,174

     

     

     

    58,501

     

     

     

    73,408

     

     

     

    131,536

     

    Restructuring expenses

     

    2,811

     

     

     

    —

     

     

     

    2,811

     

     

     

    —

     

    Total operating expenses

     

    65,750

     

     

     

    99,272

     

     

     

    212,698

     

     

     

    250,236

     

    Gain from sale of priority review voucher, net

     

    —

     

     

     

    —

     

     

     

    —

     

     

     

    92,930

     

    Loss from operations

     

    (66,919

    )

     

     

    (96,006

    )

     

     

    (234,003

    )

     

     

    (156,978

    )

    Interest income

     

    1,640

     

     

     

    2,454

     

     

     

    7,056

     

     

     

    7,961

     

    Interest expense

     

    (5,778

    )

     

     

    (4,311

    )

     

     

    (16,875

    )

     

     

    (12,331

    )

    Other income, net

     

    10,191

     

     

     

    10,631

     

     

     

    31,782

     

     

     

    30,177

     

    Loss before income taxes

     

    (60,866

    )

     

     

    (87,232

    )

     

     

    (212,040

    )

     

     

    (131,171

    )

    Income tax (expense) benefit

     

    58

     

     

     

    —

     

     

     

    37

     

     

     

    80

     

    Net loss

    $

    (60,808

    )

     

    $

    (87,232

    )

     

    $

    (212,003

    )

     

    $

    (131,091

    )

    Net loss per share - basic

    $

    (0.31

    )

     

    $

    (0.80

    )

     

    $

    (1.10

    )

     

    $

    (1.23

    )

    Net loss per share - diluted

    $

    (0.31

    )

     

    $

    (0.80

    )

     

    $

    (1.10

    )

     

    $

    (1.23

    )

    Weighted-average number of common shares used in computing net loss per share - basic:

     

    193,893

     

     

     

    109,098

     

     

     

    193,588

     

     

     

    106,924

     

    Weighted-average number of common shares used in computing net loss per share - diluted:

     

    193,893

     

     

     

    109,098

     

     

     

    193,588

     

     

     

    106,924

     

    Other comprehensive income (loss):

     

     

     

     

     

     

     

    Other comprehensive income (loss), net of tax benefit (expense) of $0.0 million for the three and nine months ended September 30, 2024 and 2023

     

    611

     

     

     

    137

     

     

     

    285

     

     

     

    1,843

     

    Total other comprehensive income (loss)

     

    611

     

     

     

    137

     

     

     

    285

     

     

     

    1,843

     

    Comprehensive loss

    $

    (60,197

    )

     

    $

    (87,095

    )

     

    $

    (211,718

    )

     

    $

    (129,248

    )

     

     

     

     

     

     

     

     

    bluebird bio, Inc.

    Condensed Consolidated Balance Sheets

    (in thousands, except per share data)

    (unaudited)

     

    As of

    September 30,

    2024

     

    As of

    December 31,

    2023

    Cash and cash equivalents

    $

    70,651

     

     

    $

    221,755

    Restricted cash

     

    48,001

     

     

     

    52,842

    Total assets

     

    465,056

     

     

     

    619,161

    Total liabilities

     

    470,842

     

     

     

    424,624

    Total stockholders' equity

     

    (5,786

    )

     

     

    194,537

     

    View source version on businesswire.com: https://www.businesswire.com/news/home/20241114895294/en/

    Get the next $BLUE alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $BLUE

    DatePrice TargetRatingAnalyst
    2/24/2025Underweight → Neutral
    Analyst
    2/24/2025$29.00Overweight
    Analyst
    11/18/2024Neutral → Underweight
    Analyst
    11/15/2024Neutral → Underweight
    JP Morgan
    11/15/2024$3.00 → $0.50Buy → Neutral
    BofA Securities
    8/15/2024Overweight → Neutral
    JP Morgan
    12/11/2023Hold → Reduce
    HSBC Securities
    12/8/2023$3.00 → $7.00Underweight → Equal-Weight
    Morgan Stanley
    More analyst ratings

    $BLUE
    SEC Filings

    See more
    • Amendment: SEC Form SC 14D9/A filed by bluebird bio Inc.

      SC 14D9/A - bluebird bio, Inc. (0001293971) (Subject)

      5/9/25 8:44:57 AM ET
      $BLUE
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Amendment: SEC Form SC 14D9/A filed by bluebird bio Inc.

      SC 14D9/A - bluebird bio, Inc. (0001293971) (Subject)

      5/6/25 7:47:43 AM ET
      $BLUE
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Amendment: SEC Form SC TO-T/A filed by bluebird bio Inc.

      SC TO-T/A - bluebird bio, Inc. (0001293971) (Subject)

      5/6/25 7:33:39 AM ET
      $BLUE
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $BLUE
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Important Information for bluebird bio Stockholders to Tender Shares for Acquisition by Carlyle and SK Capital

      bluebird bio, Inc. (NASDAQ:BLUE) ("bluebird") today reminds all stockholders, including individual stockholders, to promptly tender their shares into the tender offer by Carlyle and SK Capital to purchase all outstanding shares of bluebird common stock by 11:59 p.m. Eastern on May 12, 2025. Stockholders that hold shares of bluebird common stock through a broker or other nominee may be subject to a processing cutoff that is prior to the tender deadline, so it is important to act now. Every share tendered by stockholders is important and it is important to tender now. If a majority of the outstanding shares of bluebird common stock are not tendered, the tender offer will not be completed, a

      5/9/25 8:30:00 AM ET
      $BLUE
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Carlyle and SK Capital Receive All Required Regulatory Approvals to Complete the Acquisition of bluebird bio

      bluebird Board of Directors unanimously supports the transaction as the only viable option for stockholders to receive consideration for their shares and recommends that all stockholders immediately tender their shares into the offer Parties expect the merger to be completed promptly following the successful completion of the ongoing tender offer bluebird bio, Inc. (NASDAQ:BLUE) ("bluebird" or "the Company"), Carlyle (NASDAQ:CG) ("Carlyle"), SK Capital Partners, LP ("SK Capital") and Beacon Parent Holdings, L.P. ("Parent") announced today that all required regulatory approvals to complete the previously announced acquisition of the Company by Carlyle and SK Capital have been received. No

      5/5/25 4:00:00 PM ET
      $BLUE
      $CG
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
      Investment Managers
      Finance
    • bluebird bio confirms that Ayrmid, Ltd. has not delivered a binding offer or obtained necessary financing despite extensive engagement

      bluebird Board reaffirms unanimous recommendation in support of transaction with Carlyle and SK Capital and recommends all stockholders tender into the current agreement by May 2, 2025 bluebird bio, Inc. (NASDAQ:BLUE) ("bluebird" or "the Company") today announced that after three weeks of engagement, including a timeline extension, Ayrmid Ltd. ("Ayrmid") has not submitted a binding proposal to acquire bluebird and has not obtained necessary financing. In consultation with its financial and legal advisors, the bluebird Board of Directors (the "Board") reaffirms its recommendation in support of the transaction with Carlyle and SK Capital and recommends all stockholders tender into the curren

      4/16/25 8:00:00 AM ET
      $BLUE
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $BLUE
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    See more
    • December 8, 2023 - FDA Approves First Gene Therapies to Treat Patients with Sickle Cell Disease

      For Immediate Release: December 08, 2023 Today, the U.S. Food and Drug Administration approved two milestone treatments, Casgevy and Lyfgenia, representing the first cell-based gene therapies for the treatment of sickle cell disease (SCD) in patients 12 years and older. Additionally, one of these therapies, Casgevy, is the first FDA-approved treatment to utilize a type of novel genome editing technology, signali

      12/8/23 11:12:21 AM ET
      $BLUE
      $VRTX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
      Biotechnology: Pharmaceutical Preparations
    • August 17, 2022 - FDA Approves First Cell-Based Gene Therapy to Treat Adult and Pediatric Patients with Beta-thalassemia Who Require Regular Blood Transfusions

      For Immediate Release: August 17, 2022 Today, the U.S. Food and Drug Administration approved Zynteglo (betibeglogene autotemcel), the first cell-based gene therapy for the treatment of adult and pediatric patients with beta-thalassemia who require regular red blood cell transfusions.  “Today’s approval is an important advance in the treatment of beta-thalassemia, particularly in individuals who require ongoing

      8/17/22 2:12:27 PM ET
      $BLUE
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $BLUE
    Financials

    Live finance-specific insights

    See more

    $BLUE
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • bluebird bio Reports Third Quarter 2024 Results and Highlights Operational Progress and 2024 Guidance

      - 74 patient starts completed or scheduled to date in 2024 across bluebird's commercial portfolio - - Third quarter 2024 net revenue of $10.6 million reflects quarter-to-quarter fluctuations in drug product infusions; anticipate at least $25 million of net revenue in the fourth quarter - - Management to host conference call today, November 14, 2024 at 8:00 am ET - bluebird bio, Inc. (NASDAQ:BLUE) ("bluebird bio" or the "Company") today reported third quarter results and business highlights for the quarter ended September 30, 2024, including recent commercial and operational progress. "Patient starts more than doubled from our second to third quarter update, providing clear evidence

      11/14/24 7:00:00 AM ET
      $BLUE
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • bluebird bio Adjourns Meeting of Stockholders and Announces Third Quarter Results Call

      bluebird bio, Inc. (NASDAQ:BLUE) ("bluebird bio" or the "Company") today announced that it partially adjourned its annual meeting of stockholders ("Annual Meeting") on Wednesday, November 6, 2024, to allow the Company to solicit additional votes to obtain approval of Proposal 4, a reverse stock split, as described in the Company's definitive proxy statement filed with the Securities and Exchange Commission on September 26, 2024 (the "proxy statement"). The Company's stockholders approved Proposals 1, 2, 5, 6 and 7, and did not approve Proposal 3 during the Annual Meeting held earlier today (all proposals as described in the proxy statement). The Annual Meeting will reconvene on December 4,

      11/6/24 4:15:00 PM ET
      $BLUE
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • bluebird bio Initiates Restructuring Intended to Optimize Cost Structure and Enable Quarterly Cash Flow Break-Even in the Second Half of 2025

      Actions intended to reduce cash operating expenses by approximately 20% Management team to host conference call today, September 24 at 8:00 am ET Following a comprehensive review of its operations, bluebird bio, Inc. (NASDAQ:BLUE) today announced that the Company is implementing a restructuring intended to optimize the Company's cost structure and enable quarterly cash flow break-even in the second half of 2025. The restructuring is expected to result in a 20% reduction in cash operating expenses when fully realized in Q3 2025, compared to the prior reporting period. The initiative includes a reduction in the Company's workforce of approximately 25%. The Company's cash flow break-even tar

      9/24/24 7:00:00 AM ET
      $BLUE
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Amendment: SEC Form SC 13G/A filed by bluebird bio Inc.

      SC 13G/A - bluebird bio, Inc. (0001293971) (Subject)

      11/14/24 4:39:36 PM ET
      $BLUE
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Amendment: SEC Form SC 13G/A filed by bluebird bio Inc.

      SC 13G/A - bluebird bio, Inc. (0001293971) (Subject)

      11/14/24 4:27:32 PM ET
      $BLUE
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Amendment: SEC Form SC 13G/A filed by bluebird bio Inc.

      SC 13G/A - bluebird bio, Inc. (0001293971) (Subject)

      11/14/24 10:32:08 AM ET
      $BLUE
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $BLUE
    Leadership Updates

    Live Leadership Updates

    See more
    • 2Flo Ventures Announces Addition of Renowned Life Sciences Executive Charlotte Jones-Burton, MD, MS as a Partner

      CHICAGO, June 2, 2024 /PRNewswire/ -- 2Flo Ventures, an emerging venture capital firm and startup studio focused on the discovery, development, and commercialization of healthcare solutions that address disparities in outcomes and health equity broadly, is pleased to announce the addition of Dr. Charlotte Jones-Burton as a Partner and Head of Life Science Product Development and Strategy. 2Flo Ventures Announces Addition of Renowned Life Sciences Executive Charlotte Jones-Burton, MD, MS as a PartnerDr. Jones-Burton brings to 2Flo Ventures nearly two decades of experience in th

      6/2/24 10:15:00 PM ET
      $BLUE
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • bluebird bio Appoints O. James Sterling as Chief Financial Officer

      bluebird bio, Inc. (NASDAQ:BLUE) today announced that O. James Sterling, has been appointed chief financial officer (CFO), effective June 10, 2024. Mr. Sterling most recently served as chief financial officer of Renalytix plc, a diagnostics company focused on clinical management of kidney disease. "We are thrilled to welcome James to bluebird bio. We are confident that his extensive experience in the healthcare sector and knowledge of the capital markets will position us well as we work to prove the commercial gene therapy model, and demonstrate progress on our path to profitability," said Andrew Obenshain, chief executive officer, bluebird bio. "It is an honor to be joining bluebird bi

      5/29/24 7:00:00 AM ET
      $BLUE
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Engine Capital Sends Letter to 2seventy's Board of Directors Outlining Steps to Maximize Shareholder Value

      Believes 2seventy Could Be Conservatively Worth ~$9 Per Share if the Company Exclusively Focuses on Its Most-Valuable Asset Abecma, Reduces Corporate Overhead and Makes Improvements to the Composition of the Management Team and Board Engine Capital LP, which owns approximately 3% of 2seventy bio, Inc.'s (NASDAQ:TSVT) ("2seventy" or the "Company") outstanding shares, today announced that it sent the below letter the Company's Board of Directors (the "Board"). *** December 6, 2023 2seventy bio, Inc. 60 Binney Street Cambridge, MA 02142 Attention: Board of Directors Dear Members of the Board: Engine Capital LP (together with its affiliates, "Engine" or "we"), is a meaningful shareh

      12/6/23 8:00:00 AM ET
      $BLUE
      $TSVT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
      Biotechnology: Pharmaceutical Preparations

    $BLUE
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Chief Medical Officer Colvin Richard A sold $2,289 worth of shares (584 units at $3.92), decreasing direct ownership by 7% to 7,610 units (SEC Form 4)

      4 - bluebird bio, Inc. (0001293971) (Issuer)

      3/5/25 4:05:53 PM ET
      $BLUE
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Officer Klima Thomas J sold $1,960 worth of shares (500 units at $3.92), decreasing direct ownership by 6% to 7,878 units (SEC Form 4)

      4 - bluebird bio, Inc. (0001293971) (Issuer)

      3/5/25 4:05:41 PM ET
      $BLUE
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • President and CEO Obenshain Andrew sold $3,610 worth of shares (921 units at $3.92), decreasing direct ownership by 5% to 18,327 units (SEC Form 4)

      4 - bluebird bio, Inc. (0001293971) (Issuer)

      3/5/25 4:05:24 PM ET
      $BLUE
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $BLUE
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Bluebirdbio upgraded by Analyst

      Analyst upgraded Bluebirdbio from Underweight to Neutral

      2/24/25 7:05:14 AM ET
      $BLUE
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Analyst initiated coverage on Bluebirdbio with a new price target

      Analyst initiated coverage of Bluebirdbio with a rating of Overweight and set a new price target of $29.00

      2/24/25 7:04:33 AM ET
      $BLUE
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Bluebirdbio downgraded by Analyst

      Analyst downgraded Bluebirdbio from Neutral to Underweight

      11/18/24 4:13:05 AM ET
      $BLUE
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care